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235of all, we all agree with the authors regarding the
adverse effects of smoking on cardiovascular disease
(CVD), recognizing the importance of campaigns for
smoking cessation as a preventable risk factor and
prevention of passive smoking in preventing CVD
(2). In addition, we recently demonstrated that
smokers showed more impaired peripheral
endothelial function than never smokers, resulting
in a higher rate of in-stent restenosis in smokers
(unpublished data). Furthermore, cigarette smoking
has been known as a major risk factor in the
development of atherosclerosis and has been shown
to cause inﬂammation and modiﬁcation of the lipid
proﬁle. These data seem to be theoretically
compatible with the association with cigarette
smoking and a higher burden of necrotic core in
coronary lesions observed by a cross-sectional
intravascular ultrasound (IVUS) study (3). Because
coronary plaque progression/regression has been
known as a multifactorial process, even in the
precisely designed serial IVUS studies, it appears to
be difﬁcult to show the direct relationship between
smoking and coronary plaque progression during a
relatively short study period.
Considering the varying ﬁndings of the previous
studies, the association between smoking status and
coronary plaque progression has still been contro-
versial. As the authors of letter noted, an appropri-
ately designed serial IVUS study evaluating the
impact of smoking on coronary plaque progression
primarily is deﬁnitely warranted.*Kenichi Tsujita, MD, PhD
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Transcatheter Aortic
Valve Replacement
With Balloon-Expandable
Versus Self-Expandable ValvesCHOICE Trial ResultsWe read with interest the paper by Abdel-Wahab et al.
(1) on 1-year outcomes of the CHOICE (Randomized
Comparison of Transcatheter Heart Valves in High
Risk Patients With Severe Aortic Stenosis: Medtronic
CoreValve Versus Edwards SAPIEN XT Trial)
randomized clinical trial comparing transcatheter
aortic valve replacement (TAVR) with the balloon-
expandable (BE) Edwards SAPIEN XT valve (Edwards
Lifesciences, Irvine, California) versus self-
expandable (SE) Medtronic CoreValve (Medtronic,
Minneapolis, Minnesota). Of interest, the authors
concluded that mortality was not statistically
different between the 2 groups, but there were
numerically higher stroke rates with BE valves. These
data are interesting, but we suggest some caution in
their interpretation. Indeed, important differences
are present in the baseline characteristics between
the 2 groups. First, signiﬁcantly more women have
been enrolled in the SE group. Of note, several
studies (2,3) and a recently published meta-analysis
(4) showed that mortality after TAVR is signiﬁcantly
lower in women compared with men. Second,
patients in the BE group tended to be older
(2.3 years older) and with a reduced left ventricular
ejection fraction compared with SE patients, and
both variables are important predictors of mortality
after TAVR.
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236Another concern is that patients in the SE group
presented a signiﬁcantly higher incidence of more
than mild aortic regurgitation, a well-known predic-
tor of mortality after TAVR (5). However, the CHOICE
trial failed to show any association between aortic
regurgitation and mortality, possibly due to the
previously described imbalance in baseline
characteristics between the 2 groups.
Finally, patients in the BE group showed a trend
for an increased rate of stroke compared with SE
patients. Of interest, the authors reported an unex-
pected ﬁnding of 4 cases (3.4% of BE-implanted
patients) of early prosthetic valve dysfunction in
the BE group, possibly attributed to valve throm-
bosis, suggesting a possible link with the higher
stroke rate. However, patients enrolled in the BE
group at baseline compared with SE group also
presented a higher incidence of atrial ﬁbrillation,
despite no difference in antithrombotic therapy, that
might play a role in the higher stroke rate observed
in the BE group.*Rocco A. Montone, MD
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Versus Self-Expandable Valves
CHOICE Trial ResultsWe appreciate the thoughtful comments of Dr. Mon-
tone and colleagues concerning the 1-year clinical
outcome of the CHOICE trial, but do not share their
concerns about a differential impact of baseline
characteristics on the observed mortality rates in a
randomized setting. Among all baseline clinical and
echocardiographic characteristics of the CHOICE
population, only sex was statistically signiﬁcantly
different between the balloon-expandable (BE) and
self-expandable (SE) groups (age and baseline left
ventricular function were not signiﬁcantly different)
(1,2). As mentioned in the paper, we performed a
logistic regression analysis to adjust for sex, and
the results are essentially unchanged if sex is taken
into account (2) (unadjusted p value for all-cause
mortality at 1-year using the Fisher exact test ¼
0.37, adjusted p value for all-cause mortality at 1-
year using logistic regression ¼ 0.33).
The assumption of Dr. Montone et al. that more
than mild prosthetic valve regurgitation was not
associated with higher mortality in the CHOICE
population is not correct. As brieﬂy mentioned in the
discussion section of our paper (2), device success
(which was mainly driven by the absence of more
than mild paravalvular leaks) was independently
associated with improved survival at 1 year (adjusted
odds ratio calculated by logistic regression ¼ 0.16,
95% conﬁdence interval: 0.04 to 0.67, p ¼ 0.01). As
previously discussed, the lack of a mortality
difference between both devices despite differences
in device success could be partially explained by the
moderate sample size of this study as well as the
numerically higher rate of thromboembolic events in
the BE group, although this remains speculative.
Finally, a potential association between the
numerically higher incidence of baseline atrial ﬁbril-
lation (AF) and the occurrence of stroke in the BE group
cannot be entirely excluded. In fact, 6 of 11 stroke
events in the BE group occurred in patients with AF,
but the rate of new-onset AFwas nearly identical in the
BE group (9.8%) and SE group (9.4%, p ¼ 1.0) (2).*Mohamed Abdel-Wahab, MD
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